Cell-mediated immunity to human CMV infection: A brief overview

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Terrazzini, Nadia ^a   Kern, Florian ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; HLA ANTIGEN;

ADAPTIVE IMMUNITY; BIRTH DEFECT; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNE SYSTEM; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PERINATAL CARE; REGULATORY T LYMPHOCYTE; REVIEW; TERMINAL DISEASE;

EID: 84900536901     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-28     Document Type: Review

References (108)

1. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA: Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol 1995, 247:443-58.
2. Alford CA, Stagno S, Pass RF, Britt WJ: Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 1990, 12(Suppl 7):S745-53. (Pubitemid 20311816)
3. Stagno S, ReynoldsDW, Amos CS, Dahle AJ, McCollister FP, Mohindra I, Ermocilla R, Alford CA: Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics 1977, 59:669-78.
4. Saigal S, Lunyk O, Larke RP, Chernesky MA: The outcome in children with congenital cytomegalovirus infection. A longitudinal follow-up study. Am J Dis Child 1982, 136:896-901. (Pubitemid 12015011)
5. Rook AH: Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988, 10(Suppl 3):S460-7.
6. Griffiths PD: Current management of cytomegalovirus disease. J Med Virol 1993, 1:106-11.
7. Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martínez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, Maier AB, McElhaney JE, Moss P, Naumova E, Nikolich-Zugich J, Pera A, Rector JL, Riddell N, Sanchez-Correa B, et al.: CMV and Immunosenescence: from basics to clinics. Immun Ageing 2012, 9(23).
8. Wang GC, Kao WHL, Murakami P, Xue Q, Chiou RB, Detrick B, McDyer JF, Semba RD, Casolaro V, Walston JD, Fried LP: Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol 2010, 171:1144-52.
9. Aiello AE, Simanek AM: Cytomegalovirus and immunological aging: the real driver of HIV and heart disease? J Infect Dis 2012, 205:1772-4.
10. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE: Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS ONE 2011, 6(e16103).
11. Pawelec G, Akbar A, Beverley P, Caruso C, Derhovanessian E, Fülöp T, Griffiths P, Grubeck-Loebenstein B, Hamprecht K, Jahn G, Kern F, Koch SD, Larbi A, Maier AB, Macallan D, Moss P, Samson S, Strindhall J, Trannoy E, Wills M: Immunosenescence and Cytomegalovirus: where do we stand after a decade? Immun Ageing 2010, 7(13).
12. Reddehase MJ: Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002, 2:831-44.
13. Goodrum F, Caviness K, Zagallo P: Human cytomegalovirus persistence. Cell Microbiol 2012, 14:644-55.
14. Quinnan GV, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, Burns WH: Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982, 307:7-13. (Pubitemid 12075446)
15. Quinnan GV, Burns WH, Kirmani N, Rook AH, Manischewitz J, Jackson L, Santos GW, Saral R: HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis 1984, 6:156-63.
16. + T cells. PLoS Pathog 2013, 9(e1003635).
17. Terrazzini N, Bajwa M, Vita S, Cheek E, Thomas D, Seddiki N, Smith H, Kern F: A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular Pathology. J Infect Dis 2013.
18. Tovar-Salazar A, Patterson-Bartlett J, Jesser R, Weinberg A: Regulatory function of cytomegalovirus-specific CD4+CD27-CD28- T cells. Virology 2010, 398:158-67.
19. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T, Moreau J, Hayday AC, Willcox BE, Déchanet-Merville J: Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012, 13:872-9.
20. Pitard V, Roumanes D, Lafarge X, Couzi L, Garrigue I, Lafon M, Merville P, Moreau J, Déchanet-Merville J: Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. Blood 2008, 112:1317-24.
21. Fadda L, Körner C, Kumar S, van Teijlingen NH, Piechocka-Trocha A, Carrington M, Altfeld M: HLA-Cw*0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog 2012, 8(e1002805).
22. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-6. (Pubitemid 26332731)
23. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ: Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997, 99:1739-50. (Pubitemid 27163826)
24. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk HD: T-cell epitope mapping by flow cytometry. Nat Med 1998, 4:975-8.
25. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001, 255:27-40.
26. Kern F, Faulhaber N, Frömmel C, Khatamzas E, Prösch S, Schönemann C, Kretzschmar I, Volkmer-Engert R, Volk HD, Reinke P: Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000, 30:1676-82. (Pubitemid 30342810)
27. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ: Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202:673-85. (Pubitemid 41248418)
28. Kern F, LiPira G, Gratama JW, Manca F, Roederer M: Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 2005, 26:477-84. (Pubitemid 41139257)
29. Li Pira G, Kern F, Gratama J, Roederer M, Manca F: Measurement of antigen specific immune responses: 2006 update. Cytometry B Clin Cytom 2007, 72:77-85. (Pubitemid 46365535)
30. Gratama JW, Kern F, Manca F, Roederer M: Measuring antigen-specific immune responses, 2008 update. Cytometry A 2008, 73:971-4.
31. Alp NJ, Allport TD, van Zanten J, Rodgers B, Sissons JG, Borysiewicz LK: Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. J Virol 1991, 65:4812-20.
32. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG: Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988, 168:919-31.
33. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG: The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996, 70:7569-79. (Pubitemid 26340108)
34. Kern F, Surel IP, Faulhaber N, Frömmel C, Schneider-Mergener J, Schönemann C, Reinke P, Volk HD: Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999, 73:8179-84. (Pubitemid 29441679)
35. Lindsley MD, Torpey DJ, Rinaldo CR: HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells. J Immunol 1986, 136:3045-51. (Pubitemid 16107216)
36. Krensky AM, Reiss CS, Mier JW, Strominger JL, Burakoff SJ: Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci USA 1982, 79:2365-9. (Pubitemid 12161322)
37. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, Easterbrook P, Grey P, Smith D, McMichael AJ, Cooper DA, Rowland-Jones SL, Kelleher AD: Characterization of CD4(+) CTLs ex vivo. J Immunol 2002, 168:5954-8.
38. Riddell SR, Greenberg PD: Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995, 13:545-86.
39. Stern-Ginossar N, Weisburd B, Michalski A, Le VTK, Hein MY, Huang S, Ma M, Shen B, Qian S, Hengel H, Mann M, Ingolia NT, Weissman JS: Decoding human cytomegalovirus. Science 2012, 338:1088-93.
40. Holtappels R, Thomas D, Reddehase MJ: The efficacy of antigen processing is critical for protection against cytomegalovirus disease in the presence of viral immune evasion proteins. J Virol 2009, 83:9611-5.
41. Sauer C, Klobuch S, Herr W, Thomas S, Plachter B: Subviral dense bodies of human cytomegalovirus stimulate maturation and activation of monocyte-derived immature dendritic cells. J Virol 2013, 87:11287-91.
42. Pepperl S, Münster J, Mach M, Harris JR, Plachter B: Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 2000, 74:6132-46. (Pubitemid 30412985)
43. Walker JD, Maier CL, Pober JS: Cytomegalovirus-infected human endothelial cells can stimulate allogeneicCD4+memoryTcells by releasing antigenic exosomes. J Immunol 2009, 182:1548-59.
44. Kondo K, Xu J, Mocarski ES: Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci USA 1996, 93:11137-42. (Pubitemid 26333131)
45. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, Forman SJ, Gaal K, Bray KR, Gasior GH, Boyce CS, Sullivan LA, Southwick PC: Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010, 116:1655-62.
46. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PAH: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202:379-86. (Pubitemid 41126955)
47. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk H, Lehmkuhl H, Kern F: Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005, 201:1031-6. (Pubitemid 40524670)
48. Reddehase MJ: The immunogenicity of human and murine cytomegaloviruses. Curr Opin Immunol 2000, 12:390-6.
49. Mocarski ES: Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002, 10:332-9.
50. Doom CM, Hill AB: MHC class I immune evasion in MCMV infection. Med Microbiol Immunol 2008, 197:191-204.
51. Powers C, DeFilippis V, Malouli D, Früh K: Cytomegalovirus immune evasion. Curr Top Microbiol Immunol 2008, 325:333-59.
52. Jackson SE, Mason GM, Wills MR: Human cytomegalovirus immunity and immune evasion. Virus Res 2011, 157:151-60.
53. Noriega V, Redmann V, Gardner T, Tortorella D: Diverse immune evasion strategies by human cytomegalovirus. Immunol Res 2012, 54:140-51.
54. Lu M, Guo Q, Pasternack RF, Wink DJ, Seeman NC, Kallenbach NR: Drug binding by branched DNA: selective interaction of tetrapyridyl porphyrins with an immobile junction. Biochemistry 1990, 29:1614-24. (Pubitemid 20063396)
55. Riddell, Greenberg: T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 1997, 7:181-92.
56. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD: Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991, 146:2795-804.
57. Riddell SR, Reusser P, Greenberg PD: Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev Infect Dis 1991, 13(Suppl 11):S966-73.
58. Derhovanessian E, Larbi A, Pawelec G: Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol 2009, 21:440-5.
59. Chen S, Craen AJM de, Raz Y, Derhovanessian E, Vossen ACTM, Westendorp RGJ, Pawelec G, Maier AB: Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. Immun Ageing 2012, 9 (18).
60. Mortensen LH, Maier AB, Slagbom PE, Pawelec G, Derhovanessian E, Petersen I, Jahn G, Westendorp RGJ, Christensen K: Early-life environment influencing susceptibility to cytomegalovirus infection: evidence from the Leiden Longevity Study and the Longitudinal Study of Aging Danish Twins. Epidemiol Infect 2012, 140:835-41.
61. Derhovanessian E, Maier AB, Hähnel K, Zelba H, Craen AJM de, Roelofs H, Slagboom EP, Westendorp RGJ, Pawelec G: Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr) 2013, 35:1387-99.
62. Steininger C: Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect 2007, 13:953-63.
63. Steininger C, Puchhammer-Stöckl E, Popow-Kraupp T: Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol 2006, 37:1-9. (Pubitemid 44279524)
64. Griffiths PD: CMV as a cofactor enhancing progression of AIDS. J Clin Virol 2006, 35:489-92.
65. Derhovanessian E, Maier AB, Beck R, Jahn G, Hähnel K, Slagboom PE, Craen AJM de, Westendorp RGJ, Pawelec G: Hallmark features of immunosenescence are absent in familial longevity. J Immunol 2010, 185:4618-24.
66. Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG: The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J Virol 1999, 73:2099-108. (Pubitemid 29098114)
67. Weekes MP, Carmichael AJ, Wills MR, Mynard K, Sissons JG: Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol 1999, 162:7569-77. (Pubitemid 29277739)
68. Gratama JW, Naipal AM, Oosterveer MA, Stijnen T, Kluin-Nelemans HC, Ginsel LA, den Ottolander GJ, Hekker AC, D'Amaro J, van der Giessen M: Effects of herpes virus carrier status on peripheral T lymphocyte subsets. Blood 1987, 70:516-23. (Pubitemid 17142938)
69. Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A: Is immunosenescence infectious? Trends Immunol 2004, 25:406-10. (Pubitemid 38951080)
70. van Leeuwen EMM, Remmerswaal EBM, Vossen MTM, Rowshani AT, Wertheim-van Dillen PME, van Lier RAW, Berge IJM ten: Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004, 173:1834-41. (Pubitemid 38971617)
71. Eriksson P, Sandell C, Backteman K, Ernerudh J: Expansions of CD4+ CD28- and CD8+CD28- T cells in granulomatosis with polyangiitis and microscopic polyangiitis are associated with cytomegalovirus infection but not with disease activity. J Rheumatol 2012, 39:1840-3.
72. Morgan MD, Pachnio A, Begum J, Roberts D, Rasmussen N, Neil DAH, Bajema I, Savage COS, Moss PA, Harper L: CD4+ CD28- T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis Rheum 2011, 63:2127-37.
73. Klenerman P, Hill A: T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005, 6:873-9. (Pubitemid 43090441)
74. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB: Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006, 177: 450-8. (Pubitemid 43939158)
75. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR, Hill AB: Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 2008, 29:650-9.
76. O'Hara GA, Welten SPM, Klenerman P, Arens R: Memory T cell inflation: understanding cause and effect. Trends Immunol 2012, 33:84-90.
77. Meijer H, Dormans PH, Geelen JL, van Boven CP: Rat cytomegalovirus: studies on the viral genome and the proteins of virions and nucleocapsids. J Gen Virol 1984, 65 (Pt 4):681-95. (Pubitemid 14169977)
78. Stals FS, Bosman F, van Boven CP, Bruggeman CA: An animal model for therapeutic intervention studies of CMV infection in the immunocompromised host. Arch Virol 1990, 114: 91-107. (Pubitemid 20344715)
79. Price DA, Bitmansour AD, Edgar JB, Walker JM, Axthelm MK, Douek DC, Picker LJ: Induction and evolution of cytomegalovirus-specific CD4+ T cell clonotypes in rhesus macaques. J Immunol 2008, 180:269-80.
80. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Lifson JD, Picker LJ: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-7.
81. Hansen SG, Piatak M, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Früh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ: Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-4.
82. Bilate AM, Lafaille JJ: Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012, 30:733-58.
83. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, Boehmer H von: Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6:1219-27. (Pubitemid 43045633)
84. Punkosdy GA, Blain M, Glass DD, Lozano MM, O'Mara L, Dudley JP, Ahmed R, Shevach EM: Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens. Proc Natl Acad Sci USA 2011, 108:3677-82.
85. Belkaid Y, Rouse BT: Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-60. (Pubitemid 41716772)
86. Losikoff PT, Self AA, Gregory SH: Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012, 3:610-20.
87. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LSK, Sansom DM: Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-3.
88. Walker LSK, Sansom DM: The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011, 11:852-63.
89. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre M, Puccetti P: Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4:1206-12. (Pubitemid 37547898)
90. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen J, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204:1257-65. (Pubitemid 46919862)
91. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rötzschke O, Falk K: Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-32. (Pubitemid 47281420)
92. Peterson RA: Regulatory T cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 2012, 40:186-204.
93. Gregori S, Goudy KS, Roncarolo MG: The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012, 3(30).
94. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-6. (Pubitemid 36432314)
95. Roncarolo M, Gregori S: Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008, 38:925-7.
96. Allan SE, Song-Zhao GX, Abraham T, McMurchy AN, Levings MK: Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 2008, 38:3282-9.
97. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Levings MK: The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005, 115:3276-84. (Pubitemid 41567592)
98. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW: Helios expression is a marker of T cell activation and proliferation. PLoS ONE 2011, 6(e24226).
99. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG: Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008, 28:402-13.
100. Weiss E, Schmidt A, Vobis D, Garbi N, Lahl K, Mayer CT, Sparwasser T, Ludwig A, Suri-Payer E, Oberle N, Krammer PH: Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol 2011, 187:1684-91.
101. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Schack D von, Bluestone JA: Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012, 209:1713-22S1-19.
102. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, Xu Y, Brown K, Dyer WB, Kim M, Rose R de, Kent SJ, Jiang L, Breit SN, Emery S, Cunningham AL, Cooper DA, Kelleher AD: High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 2009, 183:2827-36.
103. Cheroutre H, Lambolez F, Mucida D: The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 2011, 11:445-56.
104. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, van Rysselberge M, Twité N, Goldman M, Marchant A, Willems F: Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med 2010, 207:807-21.
105. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW: Surface expression ofHLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000, 287 (1031).
106. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH: Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000, 164:5019-22. (Pubitemid 30305172)
107. Béziat V, Liu LL, Malmberg J, Ivarsson MA, Sohlberg E, Björklund AT, Retière C, Sverremark-Ekström E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaëlsson J, Ljunggren H, Malmberg K: NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013, 121:2678-88.
108. Paust S, Andrian UH von: Natural killer cell memory. Nat Immunol 2011, 12:500-8.